Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

South Korea approves Celltrion's COVID-19 treatment for use

09/17/2021 | 04:28am EDT

SEOUL (Reuters) - South Korea on Friday approved drugmaker Celltrion Inc's antibody COVID-19 treatment for infected adults in high-risk groups or those with severe symptoms.

Phase III clinical trials showed that the treatment significantly reduced deterioration of COVID-19 symptoms to severe levels and shortened recovery, the Ministry of Food and Drug Safety said in a statement on Friday.

The treatment lowered the rate of high-risk patients developing severe symptoms by 72% and shortened recovery by 4.12 days, the ministry said.

Celltrion said in a separate regulatory filing it plans to apply for emergency use approval and permission for the treatment from each country through continuous discussions with each regulatory agency.

Celltrion shares closed up 3.2% on Friday, compared with a 0.3% rise in the wider market.

(Reporting by Joyce Lee; editing by Jason Neely)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CELLTRION HEALTHCARE CO., LTD. 3.46% 89600 End-of-day quote.-45.03%
CELLTRION PHARM, INC. 3.57% 124600 End-of-day quote.-47.78%
CELLTRION, INC. 2.77% 222500 End-of-day quote.-38.02%
All news about CELLTRION, INC.
10/11EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation
RE
10/06U.S. to invest another $1 bln in rapid COVID-19 tests
RE
09/23Celltrion Awards Up to $626 Million from the Department of Defense to Supply Covid-19 P..
CI
09/21EU signs joint procurement deal for Eli Lilly COVID-19 treatment
RE
09/20180 LIFE SCIENCES : Plans Supply Deal With Celltrion Healthcare For Anti-TNF Product Trial..
MT
09/17South Korea approves Celltrion's COVID-19 treatment for use
RE
08/13CELLTRION : Brazil Approves Celltrion's COVID-19 Treatment for Emergency Use
MT
08/06MARKET CHATTER : Celltrion, TriLink BioTechnologies Enter Deal to Develop mRNA Vaccine Pla..
MT
08/02MARKET CHATTER : Celltrion Healthcare Secures Orders for Anticancer Biosimilars from Brazi..
MT
07/22Inhalon Biopharma, Inc. Collaborates with Celltrion, Inc. to Develop Nebulized Form of ..
CI
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Financials
Sales 2021 1 945 B 1,66 B 1,66 B
Net income 2021 600 B 0,51 B 0,51 B
Net cash 2021 241 B 0,21 B 0,21 B
P/E ratio 2021 50,0x
Yield 2021 0,01%
Capitalization 30 396 B 26 036 M 25 928 M
EV / Sales 2021 15,5x
EV / Sales 2022 12,5x
Nbr of Employees 2 034
Free-Float 76,0%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | A068270 | KR7068270008 | MarketScreener
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 222 500,00 KRW
Average target price 307 785,71 KRW
Spread / Average Target 38,3%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-38.02%26 036
MODERNA, INC.230.95%139 557
LONZA GROUP AG32.63%60 898
IQVIA HOLDINGS INC.42.93%48 923
SEAGEN INC.1.46%32 330
ALNYLAM PHARMACEUTICALS, INC.52.12%23 497